Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study.

[1]  S. Gatchalian,et al.  Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region , 2017, The Pediatric infectious disease journal.

[2]  S. Gatchalian,et al.  Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study , 2017, The Pediatric infectious disease journal.

[3]  W. Bunn,et al.  The changing epidemiology of Japanese encephalitis and New data: the implications for New recommendations for Japanese encephalitis vaccine , 2017, Tropical Diseases, Travel Medicine and Vaccines.

[4]  S. Eder,et al.  Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study. , 2016, Vaccine.

[5]  S. Hills,et al.  Estimated global incidence of Japanese encephalitis: a systematic review. , 2011, Bulletin of the World Health Organization.

[6]  A. Wilder-Smith,et al.  Japanese encephalitis: update on vaccines and vaccine recommendations , 2010, Current opinion in infectious diseases.

[7]  B. Jilma,et al.  Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up. , 2010, Vaccine.

[8]  S. Hills,et al.  Japanese encephalitis in travelers from non-endemic countries, 1973-2008. , 2010, The American journal of tropical medicine and hygiene.

[9]  C. Klade,et al.  Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. , 2010, Vaccine.

[10]  C. Klade,et al.  Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. , 2009, Vaccine.

[11]  W. J. McBride,et al.  Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. , 2008, The Journal of infectious diseases.

[12]  C. Klade,et al.  Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial , 2007, The Lancet.

[13]  Majid Ezzati,et al.  Measuring the Burden of Neglected Tropical Diseases: The Global Burden of Disease Framework , 2007, PLoS neglected tropical diseases.

[14]  I. Kurane,et al.  Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. , 2005, Vaccine.

[15]  A. Barrett,et al.  Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. , 2005, Vaccine.

[16]  N. M. Dung,et al.  NEUROLOGICAL ASPECTS OF TROPICAL DISEASE: Japanese encephalitis , 2000 .

[17]  N. M. Dung,et al.  Poliomyelitis-like illness due to Japanese encephalitis virus , 1998, The Lancet.

[18]  M. Smithson.  Statistics with confidence , 2000 .